Medicare’s GLP-1 Bridge pilot launched July 1, 2026, giving eligible Part D beneficiaries access to certain GLP-1 medications for $50 a month through Dec. 31, 2027. While Bridge is a federal program – not an employer benefit – it may affect organizations with Medicare-eligible employees. Understanding how it interacts with employer-sponsored plans can help employers communicate clearly and prepare for future benefit decisions.
- Prior Medicare Part D GLP-1 use is disqualifying. Any employees already receiving GLP-1s through a Part D drug plan are not eligible.
- The Bridge does not coordinate with the group plan. This program operates in complete isolation from employer-sponsored coverage and cannot use plans simultaneously for the same drug.
- Part D enrollment is required. Employees cannot access the Bridge until they have qualifying Part D coverage.
How the Bridge Interacts with Employer Plans
There is one key factor that affects an organization: whether an employer’s plan covers GLP-1s for weight loss. That determines whether the Bridge represents a communications consideration, a benefit access opportunity, or both:
1. The current plan covers GLP-1s for weight loss. Employers who currently cover weight loss programs will not have many employees pursuing the Bridge. According to the International Foundation of Employee Benefit Plans, 36% of employers now offer coverage for both diabetes and weight loss programs. Tracking these trends and supporting the workforce with current benefit plans are key to staying on course among the constant flow of GLP-1 changes.
2. The current plan does not cover GLP-1s for weight loss. The Bridge is a meaningful new access point for Medicare-eligible employees who also carry standalone Part D coverage and meet the clinical criteria. Proactively sharing this information is a low cost, high-value action that adds employee benefits without touching plan design or budget.
Key Employer Considerations:
Regarding GLP-1 and the implications of Bridge, your employer groups should consider the following areas:
- Credible coverage notices: Employers are required to annually notify Medicare-eligible employees whether their drug plan provides creditable coverage.
- Behavioral support: Regardless of where employees receive these medications, employers should assess their health program structure to complement GLP-1 use.
- Compliant communications: Employers should communicate the Bridge with factual and neutral information to ensure employees understand their options.
- 2028 benefits planning: As the Bridge is a temporary program and its intended successor has been delayed indefinitely, employers should begin evaluating their GLP-1 coverage position and Medicare-eligible population now. This will allow employers to make benefit decisions that are deliberate instead of reactive.
